Objective:To investigate the effect and safety of recombinant human brain natriuretic peptide in the treatment of heart failure and respiratory failure.Methods:A retrospective analysis of 78 patients with heart failure and respiratory failure who were treated in our hospital from April 2019 to April 2021 was conducted.According to the different medication regimens,they were divided into experimental group(41 cases)and control group(37 cases).Both groups were given drugs in strict accordance with the requirements of the Chinese guidelines for the diagnosis and treatment of heart failure.The experimental group added recombinant human brain natriuretic peptide on this basis.The therapeutic effect,serum index,adverse reactions and follow-up results were compared between the two groups.Results:The total effective rate of treatment in the experimental group was 90.24 % ,which was higher than 72.97 % in the control group(P<0.05).The level of NT-proBNP in peripheral serum of the experimental group was lower than that of the control group,and the left ventricular ejection fraction and 24 h urine volume were higher than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the experimental group and the control group(P>0.05).After 1 year of follow-up,the incidence of adverse events in the experimental group was lower than that in the control group(P<0.05).Conclusion:Recombinant human brain natriuretic peptide is effective in the adjuvant treatment of heart failure complicated with respiratory failure,which can improve serum indexes and reduce the risk of adverse events.The combination of drugs does not increase the incidence of adverse reactions,and the application safety is high.
Objective:To investigate the relationship between the expression of hepatocyte growth factor(HGF)and drug resistance of targeted therapy in non-small cell lung cancer.Methods:A total of 128 patients with non-small cell lung cancer who were treated with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)for targeted therapy in our hospital from June 2017 to June 2021 were selected as the research objects.According to whether EGFR-TKIs resistance was produced,the patients with drug resistance were set as the observation group,and the patients without drug resistance were set as the control group.Univariate and multivariate Logistic regression analysis was used to analyze the factors of targeted therapy resistance in patients with non-small cell lung cancer.Results:Drug resistance occurred in 56 of 128 patients with non-small cell lung cancer.There was no significant difference in gender,age,tumor location,tumor differentiation,tumor size and previous chemotherapy types between the two groups(P>0.05).There were significant differences in lymph node metastasis,HGF and c-MET positive between the two groups(P<0.05).Multivariate Logistic regression analysis showed that HGF positive and c-MET positive were independent risk factors for targeted therapy resistance in patients with non-small cell lung cancer(P<0.05).Spearman correlation analysis showed that HGF and c-MET expression were positively correlated with non-small cell lung cancer targeted therapy resistance(r=0.586,0.374,P=0.013,0.009).Conclusion:The expression of HGF and c-MET is closely related to the drug resistance of non-small cell lung cancer targeted therapy,and HGF positive and c-MET positive are independent risk factors for drug resistance of non-small cell lung cancer targeted therapy.They are expected to become biomarkers for monitoring and predicting drug resistance of non-small cell lung cancer molecular targeted therapy.
Objective:To evaluate the use of analgesics in the early stage of fractures in hospitals and provide reference for rational clinical medication.Methods:Relevant information on the use of analgesic drugs in the early stage of fracture from 2021 to 2022 was collected,and the consumption sum,defined daily dose system(DDDs),defined daily cost(DDC)and druy utilization index(DUI)were analyzed.Results:The proportion of analgesic drugs used in the early stage of hospital fractures from 2021 to 2022,celecoxib capsules,irecoxib tablets,loxoprofen sodium tablets,oxycodone hydrochloride injection,and paracetamol dihydrocodeine tablets ranked the top 5 in order;the DDDs of paracetamol dihydrocodeine tablets,celecoxib capsules,irecoxib tablets,loxoprofen sodium tablets,and tramadol hydrochloride sustained-release tablets ranked top 5.The DDC of oxycodone hydrochloride injection was the highest,and that of loxoprofen sodium tablets was the lowest.Maximum DUI value of celecoxib capsules,hydroxycodone hydrochloride injection has the lowest DUI value.Conclusion:The use of analgesics in the early stage of hospital fractures is basically reasonable,but some drugs have higher costs and are worth paying attention to.
Objective:To explore the effectiveness of high quality nursing during drug therapy for newborns in the intensive care unit.Methods:A total of 280 neonates diagnosed and treated in the intensive care unit of the hospital from January 2022 to April 2023 were selected as subjects.According to the principle of 1∶1 random coin toss,the children were divided into high quality group(140 neonates)and reference group(140 neonates).The reference group was given routine medication and nursing,and the high quality group was given high quality nursing on the basis of the reference group.The physical development,medication compliance,neurobehavioral function and intelligence of the two groups were compared.Results:The medication compliance of the high-quality group was higher than that of the reference group at the second and third weeks of nursing(P<0.05).The body weight and body length of the high-quality group were higher than those of the reference group at the second and third weeks(P<0.05).The neurobehavioral function score,mental development index and psychomotor development index of the high-quality group at the third week of nursing were higher than those of the reference group(P<0.05).Conclusion:High quality nursing can improve medication compliance,promote physical development,and improve neurobehavioral function,intellectual development index,and psychomotor development index of newborns during drug treatment in the intensive care unit.
Objective:To observe the clinical effect of Liangxue Quyu prescription combined with western medicine in the treatment of children with Henoch-Schonlein Purpura(blood heat rash syndrome).Methods:Sixty children with Henoch-Schonlein Purpura(blood heat rash syndrome)who were hospitalized in the pediatric ward of Songxian Hospital of Traditional Chinese Medicine from January 2019 to December 2021 were selected as the research objects.They were randomly divided into treatment group and control group,with 30 cases in each group.The control group was given conventional western medicine treatment,and the treatment group was given oral modified Liangxue Quyu prescription treatment on the basis of the control group.The clinical efficacy and TCM symptom scores of the two groups were compared.Results:The total effective rate of treatment group was higher than that of control group(P<0.05).After treatment,TCM syndrome scores of the two groups were lower than before treatment,and the treatment group was lower than the control group(P<0.05).Conclusion:The prescription of Liangxue Quyu prescription combined with western medicine in the treatment of children with Henoch-Schonlein Purpura(blood heat rash syndrome)can effectively improve the clinical symptoms,the curative effect is accurate,and has clinical application value.
